Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Conditions:   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   PSA Progression;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8 Interventions:   Drug: Avelumab;   Drug: Nedisertib;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials